International Conference on Advances in Radiation Oncology #ICARO2

Session

Session 16a - Prostate - H&N

16a

Jun 22, 2017, 9:00 AM

Conveners

Session 16a - Prostate - H&N

• Brendan Healy (International Atomic Energy Agency)
• Rajiv Prasad (IAEA)
• May Abdel-Wahab

Description

Learning objectives:
1. To learn the latest developments in radiotherapy for prostate cancer
2. To learn the latest developments in radiotherapy for head and neck cancer

334. Overview of radiotherapy for prostate cancer

Mr Mack Roach

6/22/17, 9:00 AM

Invited Presentation

187. Carbon Ion Radiotherapy for Prostate Cancer; a nationwide survey of the Japan Carbon-ion Radiation Oncology Study Group (J-CROS 1501)

Hidemasa Kawamura (Gunma University)

6/22/17, 9:25 AM

Clinical Radiation Oncology

Oral Presentation

**Introduction of the study;** Multi-institutional analysis of the patients with prostate cancer who have received carbon ion radiotherapy (CIRT) as the prospective study in each institute of the Japan Carbon-ion Radiation Oncology Study Group (J-CROS) was carried out.
**Methodology;** Data of patients enrolled in prospective clinical trials performed at National institute of...

335. Overview of radiotherapy for head and neck cancer

Mr Kenneth Hu

6/22/17, 9:35 AM

Invited Presentation

65. Treatment of Head and Neck cancers with modulated radiation at an Indian Centre

Tejinder KATARIA (Chairperson, Radiation Oncology, Medanat the Medicity)

6/22/17, 10:00 AM

New Technologies in Radiation Oncology/Radiotherapy

Oral Presentation

Introduction:- Head and neck cancers (HNC) constitute one of the most common cancers in the developing world. In India, approximately 556,400 cancer deaths in the year 2010, the most fatal cancers were HNC, including malignancies of the oral cavity, lip ,oro- pharynx,nasopharynx and hypopharynx. Over 60% patients present with locally advanced disease. RT planning and treatment delivery for...

23. Matrix metalloproteinaise I (MMP-1) levels as a predictive marker of oral mucositis severity among head and neck carcinoma patients undergoing radiotherapy

Jerickson Abbie Flores (Jose R. Reyes Memorial Medical Center)

6/22/17, 10:10 AM

Radiobiology

Oral Presentation

INTRODUCTION: Concurrent chemoradiotherapy is an established modality in the management of head and neck cancer. Although employed to improve quality of life, its association with several side effects remains a clinical threat. Matrix metalloproteinase-1 (MMP-1) degrades most extracellular matrix proteins including collagen. Found to increase in cancer, further rise ensues when exposed to...

337. Questions and answers

6/22/17, 10:20 AM